By 2035, will the FDA approve a drug that slows the yearly progression of Alzheimer's disease by at least 50%?
Sağlık ve TıpOne-Off8y
Manifold MarketsKYC yokDoğrulanmış sonuçlanma verisiİyi kalibreGüncel topluluk tahminiEvet 57.1%
Tahminciler
8
Soru türü
binary
Yöntem
Play-money forecasting platform
Kaynak türü
Tahmin
Piyasa verileri
9 saat önce güncellendi
Guncelligini yitirmis14 Oca 25 10:58 UTC1 Oca 35 23:59 UTC
Trendler
Kurallar
This market will be resolved based on two main criteria by January 1, 2035:
- FDA Approval: A new drug must receive official approval from the U.S. Food and Drug Administration (FDA) specifically for the treatment of Alzheimer's disease.
- Approval means the FDA has evaluated the drug's safety and efficacy through the required clinical trial phases.
- Effectiveness: The approved drug must demonstrate the ability to slow the yearly progression of Alzheimer's disease by at least 50% compared to the standard of care.
- This reduction will be measured using standardized clinical assessments, such as cognitive function tests and daily living activity evaluations, compared to the progression rates observed with existing treatments.
- The question resolves as yes even if the effect is limited to patients with early AD.
